Bermekimab

CAS No. 1401965-15-8

Bermekimab( —— )

Catalog No. M36712 CAS No. 1401965-15-8

Bermekimab (MABp1) is a humanized monoclonal antibody against interleukin-1α (IL-1α).Bermekimab has potential anti-inflammatory activity to prevent skin inflammation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 565 Get Quote
5MG 938 Get Quote
10MG 1577 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Bermekimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Bermekimab (MABp1) is a humanized monoclonal antibody against interleukin-1α (IL-1α).Bermekimab has potential anti-inflammatory activity to prevent skin inflammation.
  • Description
    Bermekimab (MABp1) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). Bermekimab prevents tumour-related inflammation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    IL Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1401965-15-8
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. McDonald JJ, et, al. Targeting IL-1α in cancer cachexia: a narrative review. Curr Opin Support Palliat Care. 2018 Dec;12(4):453-459.?
molnova catalog
related products
  • Secukinumab

    Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.

  • Daclizumab

    Daclizumab (Zenapax) is a humanized monoclonal antibody that specifically inhibits the alpha subunit of IL-2R-HA.

  • Vunakizumab

    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis .